Chronic spontaneous urticaria: Promising approach with BTKi inhibitor rilzabrutinib

First-line therapy is often not effective Chronic spontaneous urticaria: Promising approach with BTKi inhibitor rilzabrutinib

For chronic spontaneous urticaria that does not respond adequately to H1 antihistamines, Bruton tyrosine kinase inhibitors (BTKi) are emerging as a new therapeutic option: Promising results have now been published for the oral reversible BTKi rilzabrutinib.